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PDB codes for A25T-TTR, V30G-TTR, and Y114C-TTR bound to tolcapone are 6TXV, 6TXW and 
6XTK, respectively. 
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ABSTRACT
Hereditary transthyretin amyloidosis (ATTR) are diseases characterized by the extracellular 
deposition of transthyretin (TTR) amyloid fibrils. Highly destabilizing TTR mutations cause 
leptomeningeal amyloidosis, a rare, but fatal, disorder in which TTR aggregates in the brain. The 
disease remains intractable, since liver transplantation, the reference therapy for systemic ATTR, does 
not stop mutant TTR production in the brain. In addition, despite current pharmacological strategies 
have shown to be effective against in vivo TTR aggregation by stabilizing the tetramer native 
structure and precluding its dissociation, they display low brain permeability. Recently, we have 
repurposed tolcapone as a molecule to treat systemic ATTR. Crystal structures and biophysical 
analysis converge to demonstrate that tolcapone binds with high affinity and specificity to three 
unstable leptomeningeal TTR variants, stabilizing them and, consequently inhibiting their 
aggregation. Because tolcapone is an FDA-approved drug that crosses the blood-brain-barrier, our 
results suggest that it can translate into a first disease-modifying therapy for leptomeningeal 
amyloidosis.
INTRODUCTION
The misfolding and subsequent aggregation of proteins into amyloid deposits is associated 
with the onset of a variety of debilitating human disorders, affecting millions of people worldwide [1]. 
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generate toxic extracellular deposits that lead to disease. Plasma circulating TTR is synthesised by the 
liver. The protein can also be found in the cerebrospinal fluid (CSF) and in the eye, produced by the 
brain’s choroid plexus and the retinal pigment epithelial cells [2, 3], respectively. In the blood, TTR is 
one of the proteins responsible for the transport and delivery of thyroxine (T4) and retinol to cells, 
whereas, in the CSF, TTR is the primary T4 transporter [2, 4].
Amyloidogenesis of wild-type TTR (WT-TTR) is associated with senile systemic amyloidosis, 
a cardiomyopathy affecting up to 25% of the population over age 80 [5, 6]. Hereditary transthyretin 
amyloidosis comprises a life-threatening group of rare monogenic diseases inherited in an autosomal 
dominant fashion, with most affected individuals being heterozygous for one of the approximately 
140 disease-associated TTR mutations [7]. Familial amyloid polyneuropathy (FAP) [8, 9] and the 
familial amyloid cardiomyopathy (FAC) [10] are the most common forms of hereditary amyloidosis. 
A reduced number of TTR mutations lead to leptomeningeal amyloidosis, a less well characterized 
and rare phenotype restricted to the central nervous system (CNS) and defined by preferential amyloid 
deposition in the leptomeningeal vessels, the brain parenchyma and in the eyes. The predominant 
CNS symptoms include stroke, recurrent subarachnoid hemorrhage, dementia, ataxia, seizures, 
depression and periods of decreased consciousness, usually with a poor-prognosis [11, 12].
Human TTR is a 55 kDa homotetrameric protein consisting of four β-sheet rich subunits of 
127 amino acid residues each, usually labelled from A to D. The AB/CD dimer-dimer interface 
creates two identical funnel-shaped T4-binding sites located in opposite sides of the molecule [13, 14]. 
Scission along this interface is the most probable mechanism of TTR tetramer dissociation, as it is the 
weakest of the two interfaces in the tetramer [15] and constitutes the rate-limiting step in TTR 
aggregation. After tetramer dissociation, the dimers readily convert into monomers, which experiment 
tertiary structural changes to become aggregation competent units [15, 16]. Disease-associated 
mutations accelerate TTR amyloidosis by thermodynamic or kinetic destabilization of the protein [17, 
18]. 
By removing the main source of systemic mutant TTR, liver transplantation has become the 
reference therapy for hereditary TTR amyloidosis [19, 20]. However, these patients continue to 
produce mutant TTR in the choroid plexus and in the eye. Accordingly, CNS TTR deposition has 
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The pursuit of non-invasive therapies for TTR amyloidosis has fueled the development of 
small molecules that prevent tetramer dissociation by binding to the two T4 pockets, kinetically 
stabilizing the TTR native state; thus, stalling protein aggregation [23, 24]. Only one of these 
molecules reached the market for the treatment of TTR amyloidosis, the benzoxazole tafamidis [25].
Tafamidis has been shown to slow down the progression of polyneuropathy [26] and 
cardiomyopathy [27]. Accordingly, it has been approved in Europe and Japan for the treatment of 
early-stage FAP [28] and very recently by the Food and Drug Administration (FDA) for the treatment 
of TTR cardiomyopathy [27]. In contrast, to date, there are no concluding studies on the molecule’s 
ability to halt disease progression in CNS amyloidosis patients. One study suggests that it can attain 
moderate levels in CSF and the vitreous body [29], whereas others indicate that its blood-brain-barrier 
(BBB) permeability is too low to reach therapeutic concentrations able to abrogate the aggregation of 
mutant TTR in the CNS [30, 31]. 
Using a drug repurposing approach, our group identified tolcapone as a molecule that binds 
with high affinity and specificity to the two T4-binding sites of TTR, promoting its stabilization and 
preventing the formation of amyloid fibrils and cytotoxic oligomeric species [32]. Tolcapone is an 
FDA-approved molecule for Parkinson’s disease that has already passed Phase IIa clinical trials for 
FAP (ClinicalTrials.gov Identifier: NCT02191826) [33, 34]. In this study, tolcapone induced a clear 
and robust stabilization of plasmatic TTR in all patients studied, the drug was well tolerated, and 
treatment raised no safety concerns. Of note, tolcapone penetrates the BBB [35] and preliminary data 
indicated that it might inhibit the aggregation of highly-destabilized variants [32]. Together, these 
evidences suggested that tolcapone might find therapeutic application in the rare, but fatal, CNS 
amyloidosis, which, as described, cannot be treated efficiently by liver transplantation or current 
pharmacological approaches.
In this work, we have characterized in detail the activity of tolcapone on three TTR variants 
linked to familial leptomeningeal amyloidosis, A25T-TTR [36], V30G-TTR [37] and Y114C-TTR 
[38], which are among the most destabilized and fastest dissociating TTR tetramers. Our results 
indicate that tolcapone binds with high affinity to the T4-binding sites of these variants, establishing 
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reduce their aggregation. Overall, these findings converge to demonstrate that tolcapone might 
become a first broad-spectrum drug to treat TTR-related amyloidosis.
RESULTS AND DISCUSSION
Tolcapone inhibits the aggregation of TTR leptomeningeal amyloidosis-associated variants
As a first step to assess if tolcapone can be considered a candidate for treating familial 
leptomeningeal amyloidosis, we evaluated its ability to prevent the aggregation of the TTR CNS 
amyloidosis-associated variants A25T-TTR, V30G-TTR and Y114C-TTR (Fig. 1). TTR solutions 
were incubated in the absence or presence of tolcapone and aggregation was induced by acidification. 
The molecule final concentration ranged between 0 and 50 µM. Orthogonal light scattering at 340 nm 
was recorded to follow aggregation and normalized to the maximum scattering value in the absence of 
tolcapone for each individual variant. Interestingly, as shown in Fig. 1, tolcapone inhibits up to 71% 
the aggregation of A25T-TTR, 76% of V30G-TTR and reaches 100% for Y114C-TTR; the potency 
for this last mutant being very close to that exerted for WT-TTR. Remarkably, at 5 µM of tolcapone, 
which corresponds to less than 2-fold the protein concentration (3.5 µM), the inhibition was already 
evident for all the TTR variants. Ten molar equivalents of tolcapone (35 µM) reduced around 70% of 
A25T-TTR aggregation, being equivalent to the anti-aggregational activity of T4 at the same 
concentration and solution conditions [12].
Tolcapone stabilizes TTR leptomeningeal amyloidosis-associated variants under denaturing 
conditions
After demonstrating that tolcapone can inhibit the aggregation of TTR variants linked to 
familial leptomeningeal amyloidosis, we addressed whether this effect depends on native tetramer 
stabilization, as previously reported for WT-TTR and the FAC-associated V122I-TTR variant [32].
It is well established that in urea TTR monomer unfolding is preceded by tetramer 
destabilization [39] and once the tetramer is dissociated, tertiary structural changes can be monitored 
by tryptophan (Trp) intrinsic fluorescence. Accordingly, to evaluate the effect of tolcapone on the 
stability of our variants, the proteins were incubated with increasing concentrations of urea (0-9.5 M) 
for 96 h, allowing the solutions to reach the equilibrium [17, 40], both in the absence and presence of 
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unfolded protein at any given urea concentration (Fig. 2). For A25T-TTR, the obtained curves in both 
conditions are similar, indicating that, surprisingly, tolcapone does not seem to exert a significant 
stabilizing effect over this variant in the assayed conditions. In stark contrast, for V30G-TTR and 
Y114C-TTR a clear stabilizing effect is observed in the presence of tolcapone, being specially 
dramatic in the case of Y114C-TTR, where tolcapone permits > 50% of the protein to remain folded 
at 9.5 M urea, a stabilization that approaches that exerted on WT-TTR.
The low stabilization observed for A25T-TTR might indicate that in this brain aggregating 
variant, at the assay protein concentration (1.8 µM), the tetramer dissociates at such low urea 
concentrations that the obtained curves report mostly on monomer unfolding. This is consistent with 
previous findings, indicating that in the 0.72-7.2 µM protein concentration range the denaturation 
curves show a single transition that is concentration independent [18]. This suggests that, at low 
protein concentrations, A25T-TTR tetramer dissociation and monomer unfolding are not significantly 
linked. The behavior of A25T-TTR is in stark contrast with that of WT-TTR, for which it is described 
that tetramer dissociation and monomer unfolding are thermodynamically linked at the protein 
concentration used in these experiments [18]. Further evidence for these different unfolding 
mechanisms is provided by the observation that, for A25T-TTR, the urea denaturation curve assessed 
by resveratrol binding differs significantly from the one monitored by Trp intrinsic fluorescence, 
whereas for WT-TTR the two curves are nearly coincident (Fig. 3) [12, 18]. Resveratrol has been 
described to display a substantial increase in its fluorescence quantum yield when bound to at least 
one of the two T4-binding sites in the tetramer, being thus a reporter for the native state TTR 
conformation [17, 18]. 
V30G-TTR and Y114C-TTR are clearly more stable and the data herein indicates that they 
would behave like WT-TTR. Indeed, for these two mutants, the denaturation curves in the presence of 
tolcapone resemble the ones described for molecules that impose kinetic stability on TTR, stabilizing 
the AB/CD dimer-dimer interface and delaying tetramer dissociation [41, 42].
The analysis emphasizes the complexity of the denaturation mechanism of TTR 
leptomeningeal-type variants, for which, in contrast to what occurred for WT-TTR and V122I-TTR 
[32], a direct relationship between tolcapone stabilizing and anti-aggregational effects could not be 
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associated variants are so destabilized that, even in the absence of denaturant, only a fraction of the 
protein remains in a native tetrameric form in the assay conditions. We evaluated the initial tetramer 
population for each of the TTR mutants under native conditions using resveratrol binding assays (Fig. 
4). The proportion of tetramer under native conditions differed among variants, as calculated from 
resveratrol binding experiments. A25T-TTR, V30G-TTR and Y114C-TTR displayed 43.7±3.6%, 
59.5±5.0% and 96.2±10.2% of tetramer relative to that in WT-TTR, respectively. The calculated 
tetramer populations fairly correlated with the aggregation inhibitory effect that tolcapone exerts in 
these mutants.
The influence of the mutations on the quaternary structural stability of the different TTR 
mutants under native conditions was also assessed by analytical size exclusion chromatography (SEC) 
at 7 µM in phosphate buffered saline (PBS) and monitored by absorbance at 280 nm (Fig. 5). This is 
the lowest TTR concentration at which our chromatography set up has enough detection sensitivity. 
V30G-TTR and Y114C-TTR appear as a unique specie with an elution volume corresponding to that 
of the WT-TTR tetramer. In contrast, in agreement with a lower tetramer stability, A25T-TTR seems 
to adopt both higher and lower molecular weight species other than the tetramer, likely corresponding 
to soluble aggregates and a monomer, respectively. This suggests that A25T-TTR dissociates 
spontaneously at this concentration, generating unfolded monomers that assemble into the 
majoritarian high-weight species. If this is the case, the equilibrium between the tetrameric and 
monomeric forms of the mutant protein should be concentration dependent.
Effectively, when analytical SEC was performed at a higher protein concentration (20 µM), 
the elution profile was identical for all the variants, presenting a single peak with an elution volume 
compatible with the TTR tetramer. This suggests that the amount of initial tolcapone targetable 
tetramer depends on both the stability of the protein and its concentration in the assay, since both 
factors impact the equilibrium between the tetrameric and monomeric forms of TTR. It is possible 
that for highly unstable variants, tolcapone not only would stabilize the available tetramer, but might 
also displace partially the equilibrium towards the population of the tetrameric form, as a result of Le 
Chatelier’s principle.
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The above described data suggests that tolcapone can inhibit the aggregation of even highly 
destabilized mutants, as long as they remain in the tetrameric state and the molecule can bind to them. 
We used isothermal titration calorimetry (ITC) to confirm that tolcapone effectively inter-acts with 
the brain-associated variants and to determine the mechanisms of binding. The thermodynamic 
parameters (∆G, ∆H, -T∆S) for the  binding reactions as well as the cooperativity of the interaction 
were analyzed for the three mutants and WT-TTR according to two models: (1) two identical, but 
independent binding sites; (2) two identical and cooperative binding sites [43, 44]. Our data indicated 
that tolcapone binds with high affinity to the first TTR T4-binding site of all proteins, but they exhibit 
differences in the degree of cooperativity for the binding to the second T4 pocket (Table 1 and Fig. 6). 
Importantly, although we first reported that tolcapone binds to WT-TTR with a weak negative 
cooperativity [32], a reevaluation of the protein-ligand interaction in the present study revealed that 
under the present assay conditions, the interaction is best described as non-cooperative, with Kd = 29 
nM. Binding of tafamidis to WT-TTR under the same conditions was assessed as a control and, as 
expected, a strong negative cooperativity was found, displaying Kd1= 9.9 nM and Kd2= 260 nM 
values, consistent with those previously reported [25]. In agreement with three recent studies [32, 45, 
46], these data confirm that the concentration of tolcapone required to occupy simultaneously the two 
WT-TTR T4 cavities is significantly lower than that of tafamidis in the same conditions, and therefore 
that tolcapone is a stronger stabilizer of this protein.
The binding of tolcapone to V30G-TTR and Y114C-TTR was also non-cooperative, with Kds 
for the two binding sites of 110 nM and 45 nM, respectively, indicating that tolcapone binds more to 
the less destabilized Y114C-TTR mutant. Indeed, although the binding of tolcapone to Y114C-TTR is 
slightly weaker than to WT-TTR, the ∆G of the interactions are fairly similar, justifying why, for 
these initially folded and tetrameric proteins, tolcapone exerts a very similar anti-aggregational effect, 
being able to abrogate completely TTR deposition at 1:1 T4-binding sites:tolcapone ratio (Fig. 1). In 
sharp contrast to the other two leptomeningeal variants, the binding of tolcapone to A25T-TTR 
displays a high negative cooperativity, reflected in a Hill coefficient (nH) of 0.25. Accordingly, 
whereas the binding to the first site is strong, with Kd1 = 63 nM, the affinity for the second cavity is 
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Irrespectively of the considered TTR mutant and T4 pocket, the binding is always enthalpically 
driven. This is important because it has been suggested that the enthalpic component of binding plays 
a predominant role in stabilizing TTR [46] and enthalpic forces correlate with the selectivity of 
transthyretin binding ligands in plasma [47], explaining why tolcapone binds selectively and stabilizes 
TTR in the blood of healthy volunteers and patients bearing the polyneuropathy-associated V30M 
mutation [32, 34]. From our thermodynamic data, the same should be true for the TTR CNS 
amyloidosis-associated variants in the brain, since the enthalpic component of the binding for these 
unstable mutants is very similar to the one exhibited for WT-TTR (Fig. 6).
Tolcapone binds TTR leptomeningeal amyloidosis-associated variants at the dimer-dimer 
interface
The fact that enthalpic contributions dominate the binding of tolcapone to the three mutant 
proteins, suggests that, as previously shown for WT-TTR [32], there exist specific interactions 
between the protein and the ligand. To confirm that these destabilized brain variants could 
accommodate tolcapone in their tetrameric structure, we obtained crystals of A25T-TTR, V30G-TTR 
and Y114C-TTR in the presence of tolcapone that diffracted beyond 1.60, 1.15 and 1.69 Å resolution, 
respectively (Fig. 7 and Table 2).
These high-resolution crystal structures clearly indicated the placement of tolcapone in the 
butterfly-shaped electron density map located in the “weak” dimer–dimer interface of TTR tetramer. 
As expected, the three new structures were virtually identical to that of WT-TTR in the presence of 
tolcapone (PDB: 4D7B), with overall root-mean-square deviation values for the Cα of 0.20 Å for 
A25T-TTR (PDB: 6TXV), 0.45 Å for V30G-TTR (PDB: 6TXW) and 0.43 Å for Y114C-TTR (PDB: 
6XTK). A closer view into the mutation sites confirms that the mutations do not disturb the structure 
of TTR and indeed, the local environment around the mutated residues remains unaltered (Fig. 8). 
This is consistent with the reported data for a vast majority of mutant TTR crystal structures [48]. To 
the best of our knowledge, the structure of V30G-TTR/tolcapone complex (PDB:6TXW), represents 
the first one for this protein variant. Val30 maps to the monomer B-strand, our structure indicating 
that the removal of the side chains of the four buried Val30 residues leads only to minor perturbations 
of the native tetrameric structure, which are restricted to the vicinity of the mutated residues, e.g. the 
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factor of Val71 in V30G-TTR remains similar to the one measured in the WT-TTR/tolcapone 
complex structure, indicating that the mutation does not even affect local flexibility. The structure of 
the Y114C-TTR/tolcapone complex is the first one to show that a kinetic stabilizer can diffuse into 
the T4-binding site of this particular mutant.
  In all structures, tolcapone binds to the TTR tetramer in the forward mode, with the 4-
methyl-phenyl ring occupying the inner binding cavity and the 3,4-dihydroxy-5-nitrophenyl ring of 
tolcapone oriented to the outer biding cavity. The presence of tolcapone inside of the T4 binding 
pocket stabilizes the orientation of key residues that form the halogen binding pockets (HBP) HBP1-
1’ (Lys15 and Leu17), HBP2-2’ (Ala108 and Leu110) and HBP3-3’ (Ser117 and Thr119), as inferred 
from their very well-defined electron maps (Fig. 9). This results in virtually identical polar, 
hydrophobic contacts and electrostatic interactions inside the T4 pocket to those stabilizing the 
tetramers in WT-TTR/tolcapone complex structure, including a specific hydrogen bond interaction 
between the carbonyl group of tolcapone and the hydroxyl side chain of Thr119. The distances 
between the carbonyl group of tolcapone and the hydroxyl side chain of Thr119 in our structures are 
similar to the ones observed in the WT-TTR/tolcapone structure and suggest the formation of 
hydrogen bonds (Table 3). These bonds are buried in the low dielectric context of the T4 pocket, in 
such a way that these interactions are predicted to be strong (Fig. 7 and Table 3). The establishment of 
hydrogen bonds between kinetic stabilizers and TTR residues in the inner binding cavity seems to be 
an important determinant of the binding affinity [32, 46].   
As in the case of WT-TTR, in the leptomeningeal amyloidosis mutants the ε-amino groups of 
Lys15/Lys15’ are sandwiched between the hydroxyl groups of the phenyl ring of tolcapone and the 
carboxylate group of Glu54 (Fig. 7 and Table 3). These specific electrostatic interactions by Lys15 
close the cavity around tolcapone hampering the entrance of solvent into the pocket and stabilizing 
the protein-compound complex.  
The new structures highlight how the tolcapone-protein interactions at the T4-binding site in 
the “weak” dimer–dimer interface are not significantly affected by the mutations, providing an 
explanation for the enthalpy driving binding of the TTR CNS amyloidosis-associated variants and 
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kinetic stabilization of the tetramer once the molecule occupies the hormone-binding sites of the 
pathogenic proteins.
CONCLUSIONS
In the present study, we have described in detail the activity of tolcapone, a potent kinetic 
stabilizer originally intended to treat Parkinson’s disease, on TTR variants associated to 
leptomeningeal amyloidosis, a rare, but fatal form of amyloidosis. We could confirm that A25T-, 
V30G- and Y114C-TTR variants present lower structural stability compared with WT-TTR, 
especially A25T-TTR. Mutations impact the tetramer-monomer equilibrium, lowering the ability of 
these variants to remain in the functional native tetrameric structure, and hence enhancing the protein 
susceptibility to aggregation. Our study demonstrates that tolcapone binds strongly and canonically at 
the T4-binding sites of all the assayed TTR leptomeningeal amyloidosis-associated variants, restoring 
the structural stability of the tetramer and, consequently, inhibiting the pathogenic protein 
aggregation. This activity, together with the compound’s ability to pass the BBB, suggests that 
tolcapone might become a first broad spectrum pharmacologic treatment for all forms of TTR-related 
amyloidosis, including the devastating CNS forms of the disease.
All in all, our study provides solid biophysical and structural rational for a recent proof of 
principle clinical trial aimed to test the ability of tolcapone to stabilize TTR in symptomatic and 
asymptomatic leptomeningeal TTR patients (ClinicalTrials.gov Identifier: NCT03591757).
MATERIALS AND METHODS
TTR expression and purification
The vectors coding for TTR variants were prepared by PCR-site directed mutagenesis using 
the QuickChange Lightning kit (Agilent technologies, Santa Clara, California, USA). pET28a vector 
(Novagen, Addgene, Cambridge, USA) encoding for the WT protein was used as a template. 
For protein expression, Escherichia coli BL21 (DE3) cells, previously transformed with the 
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to an optical density of 0.8 at 600 nm, and the culture induced with 1 mM isopropyl β-D-
thiogalactopyranoside for 16 h. Cells were harvested by centrifugation and sonicated, the soluble 
fraction was recovered by centrifugation. The TTR-containing fraction was obtained by two 
consecutive steps of ammonium sulphate precipitation (50 and 90% respectively). The precipitate was 
solubilized in 25 mM Tris-HCl, pH 8, and dialysed against the same buffer. The sample was loaded 
onto a HiTrap Q HP column (GE Healthcare, Illinois, USA) and eluted with a linear gradient 0 – 0.5 
M NaCl in 25 mM Tris-HCl, pH 8. The TTR-enriched fractions were precipitated in 90% ammonium 
sulphate and the obtained precipitate redissolved in a small volume of buffer (25 mM Tris, 100 mM 
NaCl, pH 8). TTR was finally purified by gel filtration chromatography on a HiLoad 26/600 Superdex 
75 prep grade column (GE Healthcare) and eluted with 25 mM Tris, 100 mM NaCl. Purest fractions 
were combined and stored at -20 °C. Protein concentration was determined spectrophotometrically at 
280 nm using an extinction coefficient of 77 600 M-1 cm-1. All the TTR variants, including the WT, 
were expressed and purified following the same procedure.
TTR aggregation inhibition in vitro
TTR solutions (7 µM in 10 mM sodium phosphate, 100 mM KCl, 1 mM EDTA, 1 mM DTT, 
pH 7.0) were incubated with increasing concentrations of tolcapone for 30 min at 37 °C. Since the 
stock solutions of tolcapone were prepared in dimethylsulphoxide (DMSO), the percentage of DMSO 
in all the samples was adjusted to 5% (v/v). After the incubation period, the pH was dropped to 5.0 
via dilution 1:1 with acidification buffer (100 mM sodium acetate, 100 mM KCl, 1 mM EDTA, 1 mM 
DTT, pH 5.0) and the samples were incubated for more 22 h at 37 °C. For WT-TTR and Y114C-TTR, 
a pH of 4.2 and an incubation period of 72 h were used instead.  The formation of aggregates was 
assessed by light scattering, with the excitation and emission wavelengths set at 340 nm, using a 
Varian Cary Eclipse Fluorescence Spectrophotometer (Agilent technologies). TTR aggregation was 
considered maximum in the absence of tolcapone (100% aggregation).
Urea denaturation curves in the absence or presence of tolcapone
Denaturation curves were obtained as described previously [40]. TTR solutions at 1.8 µM in 
PBS were incubated for 30 min with tolcapone and urea in 50 mM sodium phosphate, 100 mM KCl, 
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prepared with DMSO, instead of tolcapone. The concentration of urea in the solutions was verified by 
refractive index, using a Manual Hand-held Refractometer HR901 (A. Krüss Optronic, Germany). 
After 96 h incubation at RT, the fraction unfolded was determined by intrinsic fluorescence 
spectroscopy, using a FP-8200 Spectrofluorometer (Jasco, Easton, USA). The samples were excited at 
295 nm, allowing the selective excitation of the Trp residues on the protein, and fluorescence 
emission spectra were recorded from 310 to 400 nm. Upon denaturation, the Trp residues become 
more solvent-exposed and the maximum fluorescence changes from 335 nm to 355 nm, 
approximately. The 355/335 nm fluorescence emission intensity was normalized from minimum 
(folded) to maximum (unfolded), with the maximum being the sample without tolcapone, and plotted 
as a function of urea concentration.
Urea mediated transthyretin dissociation measured by resveratrol binding
A25T- and WT-TTR solutions (1.8 µM in PBS) were incubated with different concentrations 
of urea buffered with 50 mM sodium phosphate, 100 mM KCl, 1 mM EDTA and 1 mM DTT (pH 7.0) 
for 96 h at RT. After this time, 1.8 µl of resveratrol from a 1 mM stock solution in DMSO was added 
to a 100 µl sample just before the measurement, in order not to shift the equilibrium towards the 
tetramer [17]. The incubation time with resveratrol was the same for all samples. The samples were 
excited at 320 nm and the fluorescence recorded from 350 to 550 nm, using a FP-8200 
Spectrofluorometer (Jasco). The fluorescence emission intensity of resveratrol at 394 nm was used to 
calculate the amount of non-tetrameric TTR and plotted as a function of urea concentration.  
Resveratrol binding to TTR
In order to assess resveratrol binding to TTR, 1.8 µl of resveratrol from a 1 mM stock solution 
in DMSO were added to 100 µl TTR samples (1.8 µM in PBS) and the samples were excited at 320 
nm, using a FP-8200 Spectro-fluorometer (Jasco). The resveratrol fluorescence intensity at 394 nm 
was used as an indicative of the amount of tetrameric TTR present in the samples. The difference 
between TTR leptomeningeal amyloidosis-associated variants and WT-TTR was analysed by one-
way ANOVA Dunnett test using GraphPad Prism 6.0 software (GraphPad Software Inc.). p ˂ 0.05 
was considered statistically significant.
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TTR samples (500 µl at 7µM or 100 µl at 20 µM, in PBS) were filtered and injected into a 
Superdex 75 10/300 GL column (GE Healthcare), previously equilibrated with PBS. Elution was done 
with the same buffer, at a flow rate of 0.4 ml/min, and monitored by absorbance at 280 nm, which 
was normalized from 0 to 1.
Isothermal titration calorimetry
The thermodynamic parameters that describe the interaction between TTR and tolcapone were 
determined by ITC, using a MicroCal Auto-iTC200 Calorimeter (MicroCal, Malvern-Panalytical, 
UK). A25T-, Y114C- and WT-TTR at 5 µM located in the calorimetric cell were titrated against 
tolcapone at 100 µM in the injection syringe in PBS buffer pH 7.0, 100 mM KCl, 1 mM EDTA, 2.5% 
DMSO, at 25 °C. A stirring speed of 750 rpm. and 2 µl injections were programmed, with consecutive 
injections separated by 150 s to allow the calorimetric signal (thermal power) to return to baseline. 
For V30G-TTR the concentration of protein was increased to 20 µM, since the concentration of TTR 
able to bound tolcapone was low. For each protein, two replicates were performed, and the 
experimental data was analyzed with a general model for a protein with two ligand-binding sites [43, 
44] implemented in Origin 7.0 (OriginLab), which allows to establish whether the two binding sites 
are identical and independent. Appropriate control blank experiments were performed to test for 
unwanted heat artefacts or unspecific phenomena.
Crystal structures of TTR/tolcapone complexes
Co-crystals of A25T-TTR/tolcapone, V30G-TTR/tolcapone and of Y114C-TTR/tolcapone 
were obtained as described previously [32]. Briefly, purified proteins (140 µM) were incubated with 
tenfold molar excess of ligand for 5 min at 22 °C. The complex was crystallized at 18 °C by hanging-
drop vapor diffusion by mixing 1 µl of the complex with 1 µl of the reservoir solution containing 25 
and 30% PEG 400, 200 mM CaCl2, 100 mM HEPES, pH 7.0-7.5. Since PEG400 is a cryoprotectant 
itself, crystals were removed from the drop and directly flash-frozen in liquid nitrogen before 
diffraction analysis. Diffraction data were recorded from PEG400cryo-cooled crystals (100 K) at the 
ALBA synchrotron in Barcelona (BL13-XALOC beamline) [49]. Data were integrated and merged 
using XDS [50] and scaled, reduced and further analyzed using CCP4 [51]. The structure of 
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(1.17.1_3660) [52] using the crystal structure of TTR (PDB code 1F41) as a search model. The initial 
electron density maps showed the well-defined electron density map corresponding to tolcapone in 
the TTR dimer–dimer interface. Refinement was performed with Phenix [52] and model building was 
performed with COOT [53]. Ramachandran analysis shows 98.0% of residues (230) are in preferred 
regions and only 2.0% of residues (4) are in allowed regions for the A25T-TTR/tolcapone structure. 
For the V30G-TTR/tolcapone structure, 98.0% of residues (235) are in preferred regions and only 
2.0% of residues (4) are in allowed regions. For the Y114C-TTR/tolcapone structure, 96.0% of 
residues (227) are in preferred regions and only 4.0% of residues (10) are in allowed regions. 
Refinement and data statistics are provided in Table 2. Figures were prepared with PyMOL (DeLano 
Scientific, LLC).
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FIGURE LEGENDS
Fig. 1. Tolcapone effect over the aggregation of TTR leptomeningeal amyloidosis-associated variants. 
(A) A25T-TTR (in red), (B) V30G-TTR (in blue), (C) Y114C-TTR (in green) and WT-TTR (in 
black). Light scattering at 340 nm was measured and plotted as percentage of TTR aggregation.  The 
values represent mean ± s.e.m (n=3).
Fig. 2. Tolcapone effect on urea-induced denaturation of TTR leptomeningeal amyloidosis-associated 
variants. (A) A25T-TTR, (B) V30G-TTR, (C) Y114C-TTR and (D) WT-TTR. Black squares 
represent the control without tolcapone, while gold and magenta squares correspond to the samples 
incubated with 20 and 50 µM of tolcapone, respectively. The values represent mean ± s.e.m (n=3).
Fig. 3. Urea denaturation of the leptomeningeal-associated TTR variant A25T-TTR and WT-TTR. 
Stability of A25T-TTR (in red) and WT-TTR (in black) was assessed both by resveratrol binding 
(filled circles, left axis) and Trp intrinsic fluorescence (open circles, right axis). Raw resveratrol 
binding and Trp intrinsic fluorescence data is shown in (A) and (B). These values were used to 
calculate the non-tetrameric fraction and unfolded fraction, respectively, which are presented in (C) 
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Fig. 4. Resveratrol binding of TTR leptomeningeal amyloidosis-associated variants. Resveratrol 
fluorescence at 394 nm when incubated with A25T-TTR (in red), V30G-TTR (in blue), Y114C-TTR 
(in green) and WT-TTR (in black). The values represent mean ± s.e.m (n=3). One-way ANOVA 
Dunnett test revealed differences between A25T- and V30G-TTR binding to resveratrol, in 
comparison to WT-TTR; *p ˂ 0.05 and **p ˂ 0.01. 
Fig. 5. Effect of protein concentration on the quaternary structure adopted by TTR leptomeningeal 
amyloidosis-associated variants. (A-D) Elution profiles of A25T-TTR (in red), V30G-TTR (in blue), 
Y114C-TTR (in green) and WT-TTR (in black) at 7 (solid line) or 20 µM (dashed line).
Fig. 6. Calorimetric titration of TTR leptomeningeal amyloidosis-associated variants with tolcapone. 
(A) The top panel (thermogram) shows how the thermal power changes with time. The bottom panel 
(binding isotherm) is obtained from the transformation of the thermogram and represents the 
normalized heat of reaction per injection as a function of the ratio between the molar concentration of 
tolcapone and protein. The solid line in the binding isotherm corresponds to the best fitting to each 
curve. (B) Graphical representation of ∆G (dark bars), ∆H (light bars) and -T∆S (striped bars) for the 
binding of tolcapone to the first and second site of A25T-TTR (in red), V30G-TTR (in blue), Y114C-
TTR (in green) and WT-TTR (in black). In the case of V30G-, Y114C- and WT-TTR, the binding 
parameters for both sites are the same.
Fig. 7. Crystal structures of A25T-TTR, V30G-TTR and Y114C-TTR in complex with tolcapone. (A) 
Global view of TTR variants bound to tolcapone (cartoon representation). The electron density maps 
of the two tolcapone-binding sites of tolcapone are depicted. The position of the mutated residues in 
the structure is specified with asterisks. Dashed lines represent the two-fold symmetry axis of the 
dimer–dimer interface. (B) Detailed and close-up views of one of the TTR tolcapone-binding sites of 
the variants (PDB: 6TXV, 6TXW, 6XTK); tolcapone and some of the TTR tetramer residues in 
contact with it are represented by sticks. (C) Close-up views of the electron density map of the 
mutated residues. All structures were generated with PyMOL (DeLano Scientific, LLC).
Fig. 8. Comparison between the crystal structures of WT-TTR with A25T-TTR, V30G-TTR and 
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V30G (raspberry) and Y114C (olive) variant structures. (Right) Superposed tetramers are depicted in 
cartoon representation and tolcapone molecules are showed in stick. (Left) Close up view showing the 
local environment of the mutated residues in monomer A (stick representation), Thr25, Gly30 and 
Cys114 are colored by elements. The overall root-mean-square deviation for the superposed Cα atoms 
are 0.20 Å, 0.45 Å and 0.43 Å, respectively. All structures were generated with PyMOL (DeLano 
Scientific, LLC).
Fig. 9. Stereo images of TTR leptomeningeal amyloidosis-associated variants and electron density 
maps of tolcapone and of residues involved in binding. Stereo views of (A) A25T-TTR, (B) V30G-
TTR and (C) Y114C-TTR in complex with tolcapone with a 2Fo-Fcmap (blue mesh) contoured at 1.0 
σ. All structures were generated with PyMOL (DeLano Scientific, LLC).
TABLES
Table 1. Thermodynamic parameters obtained by ITC experiments for the binding of tolcapone to 
































A25T 0.063 -9.8 -17.1 7.3 3.1 -7.5 -12.3 4.8 0.25
V30G 0.110 -9.5 -12.3 2.8 0.110 -9.5 -12.3 2.8 1
Y114C 0.045 -10.0 -14.4 4.4 0.045 -10.0 -14.4 4.4 1
WT 0.029 -10.3 -8.8 -1.5 0.029 -10.3 -8.8 -1.5 1





















Table 2. Data collection and refinement statistics of transthyretin variants in complex with 
tolcapone*.  
*Values in parenthesis are for the last resolution shell.
Table 3. Comparison of the interatomic distances (in Å) between the two tolcapone molecules of 
the tetramer and residues of WT-TTR and TTR variants that form HBP1 and -1' and HBP2 and -
2' binding sites*.
* Values in parenthesis correspond to the second tolcapone molecule.
A25T-TTR V30G-TTR Y114C-TTR
Data collection
Space group P212 21 P212 21 P212 21
Unit cell parameters (Å)  43.83, 65.41, 84.67 43.67, 65.63, 84.35   42.92, 65.74, 83.95
Wavelength (nm) 0.9794 0.9790 0.9795
Resolution range (Å) 42.34-1.55 65.63-1.15 65.74-1.69
Rmerge 0.04(0.47) 0.12(0.96) 0.05(0.90)
CC1/2 0.99(0.92) 0.98(0.63) 0.99(0.63)
I/σI 23.5(3.8) 8.1(1.5) 8.0(0.9)
Completeness (%) 99.5(98.2) 96.5(95.3) 99.4(97.0)
Multiplicity 5.4(5.0) 6.3(5.1) 3.4(3.2)
Structure refinement
Resolution range (Å) 42.33-1.60 65.63-1.15 38.22-1.70
No. of unique reflections 32836 82985 26585
Rwork/Rfree (%) 19.0/21.5 15.9/18.5 19.2/22.0
No. of atoms 2070 2165 1905
Protein 1854 1854 1764
Ligands 40 40 40
Water molecules 188 279 105
Average B factors (Å2) 26.1 25.7 42.6
Protein 25.3 23.8 42.4
Ligands 25.1 21.7 44.5
Water 34.5 39.5 45.2
RMS deviations
   Bonds (Å) 0.003 0.007 0.009
   Angles (o) 0.60 0.89 0.96
PDB code 6TXV 6TXW 6XTK
WT-TTR A25T-TTR V30G-TTR Y114C-TTR
Thr119 OG1 - tolcapone O13 2.6 (2.5) 2.6 (2.6) 2.5 (2.5) 3.0 (3.0)
Lys15 NZ – tolcapone O8 2.7 (2.9) 2.8 (2.8) 3.1 (2.7) 2.9 (2.6)
Lys15 NZ - Glu54 OE2 2.8 (2.9) 3.2 (3.3) 3.1 (3.4) 2.9 (3.9)
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